Strikingly, patients with luminal-type breast cancer co-expressing MET and CD47 displayed a 10.3 year mean overall-survival difference compared to patients expressing neither MET or CD47 identifying a new subset of breast cancer patients with an extremely poor prognosis (Figure 1F, Table 2 and Supplementary Table 1, p<0.001 by log-rank test, Cox proportional hazards model: HR=8.0, 95% CI=2.7–23.2, p<0.001). The gene discussed is CD47; the disease is breast cancer.